Sublingual apomorphine (APL-130277) for the acute conversion of OFF to ON in Parkinson's disease

Movement Disorders

Volumn 31, Issue 9, 2016, Pages 1366-1372

  Hauser, Robert A ^a   Olanow, C Warren ^b   Dzyngel, Bruce ^c   Bilbault, Thierry ^c   Shill, Holly ^d   Isaacson, Stuart ^e   Dubow, Jordan ^c   Agro, Albert ^c  

^a UNIVERSITY OF SOUTH FLORIDA   (United States)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^c Cynapsus Therapeutics Inc   (Canada)

^d BARROW NEUROLOGICAL INSTITUTE   (United States)

^e Parkinson's Disease and Movement Disorder Center of Boca Raton   (United States)

Author keywords

APL 130277; apomorphine; fluctuations; OFF periods; Parkinson's disease; sublingual; treatment

Indexed keywords

ANTIPARKINSON AGENT; APL 130277; APOMORPHINE; LEVODOPA; TRIMETHOBENZAMIDE; UNCLASSIFIED DRUG;

ADULT; APATHY; ARTICLE; BALANCE DISORDER; BEHAVIOR DISORDER; CLINICAL ARTICLE; DIZZINESS; DOSE CALCULATION; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG FORMULATION; DRUG SAFETY; DRUG TOLERABILITY; DYSKINESIA; DYSPHAGIA; FATIGUE; FEMALE; HEADACHE; HUMAN; HYPERHIDROSIS; MALE; MULTICENTER STUDY; NAUSEA; OPEN STUDY; ORTHOSTATIC HYPOTENSION; PARKINSON DISEASE; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SOMNOLENCE; TREATMENT DURATION; TREATMENT RESPONSE; UNIFIED PARKINSON DISEASE RATING SCALE; YAWNING;

EID: 84985919964     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.26697     Document Type: Article

References (18)

1. Ahlskog JE, Muenter MD. Frequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literature. Mov Disord 2001;16(3):448–458.
2. Mouradian MM, Heuser IJ, Baronti F, Fabbrini G, Juncos JL, Chase TN. Pathogenesis of dyskinesias in Parkinson's disease. Ann Neurol 1989;25(5):523–526.
3. Stocchi F, Vacca L, Ruggieri S, Olanow CW. Intermittent vs continuous levodopa administration in patients with advanced Parkinson disease: a clinical and pharmacokinetic study. Arch Neurol 2005;62(6):905–910.
4. Chapuis S, Ouchchane L, Metz O, Gerbaud L, Durif F. Impact of the motor complications of Parkinson's disease on the quality of life. Mov Disord 2005;20(2):224–230.
5. Olanow CW, Kieburtz K, Odin P, et al. Continuous intrajejunal infusion of levodopa-carbidopa intestinal gel for patients with advanced Parkinson's disease: a randomised, controlled, double-blind, double-dummy study. Lancet Neurol 2014;13(2):141–149.
6. Merims D, Djaldetti R, Melamed E. Waiting for ON: a major problem in patients with Parkinson disease and ON/OFF motor fluctuations. Clin Neuropharmacol 2003;26(4):196–198.
7. US WorldMeds, LLC. Apokyn® [US prescribing information]. Louisville, KY: US WorldMeds; 2012.
8. Dewey RB Jr, Hutton JT, LeWitt PA, Factor SA. A randomized, double-blind, placebo-controlled trial of subcutaneously injected apomorphine for parkinsonian off-state events. Arch Neurol 2001;58(9):1385–1392.
9. LeWitt PA, Ondo WG, Van Lunen B, Bottini PB. Open-label study assessment of safety and adverse effects of subcutaneous apomorphine injections in treating “off” episodes in advanced Parkinson disease. Clin Neuropharmacol 2009;32(2):89–93.
10. Stacy M, Silver D. Apomorphine for the acute treatment of “off” episodes in Parkinson's disease. Parkinsonism Relat Disord 2008;14(2):85–92.
11. Lees A, Chaudhuri R, Isaacson S. Twenty years of apomorphine therapy—how does it compare to levodopa? Highlights of a Satellite Symposium. Paper presented at : 18th International Congress on Parkinson's Disease and Movement Disorders; June 2014; Stockholm, Sweden.
12. Campbell A, Kula NS, Jeppsson B, Baldessarini RJ. Oral bioavailability of apomorphine in the rat with a portacaval venous anastomosis. Eur J Pharmacol 1980;67(1):139–142.
13. Hauser RA, Reichmann H, Lew M, Asgharian A, Makumi C, Shulman KJ. Long-term, open-label study of once-daily ropinirole prolonged release in early Parkinson's disease. Int J Neurosci 2011;121(5):246–253.
14. Lieberman A, Ranhosky A, Korts D. Clinical evaluation of pramipexole in advanced Parkinson's disease: results of a double-blind, placebo-controlled, parallel-group study. Neurology 1997;49(1):162–168.
15. Boehringer Ingelheim International GmbH. Mirapex® [prescribing Information]. Ingelheim am Rhein, Germany: Boehringer Ingelheim International GmbH; 2013.
16. GlaxoSmithKline. Requip® [US prescribing Information]. Brentford, UK: GlaxoSmithKline; 2009.
17. GlaxoSmithKline. Requip XL® [US prescribing Information]. Brentford, UK: GlaxoSmithKline; 2008.
18. Hauser RA, Isaacson S, Clinch T, Tigan/Apokyn Study I. Randomized, placebo-controlled trial of trimethobenzamide to control nausea and vomiting during initiation and continued treatment with subcutaneous apomorphine injection. Parkinsonism Relat Disord 2014;20(11):1171–1176.